Doctor, you recently hosted a webinar which was a success, given the high number of participants and interesting questions received (‘La Laserterapia MLS® Robotizada para el manejo y rehabilitación del dolor en pacientes post-COVID: casos clínicos exitosos’ - ‘Robotized MLS® Laser Therapy for the management and rehabilitation of pain in post-COVID patients: successful clinical cases’). It was a very successful seminar, especially since you were one of the first doctors to share their experience, given that this topic is kind of a taboo one that nobody wants to talk about. What were the main advantages of the MLS® Laser Therapy in treating your patients? Was the progress tangible and fast, did they start to feel better in a short time? What was your experience in this regard?
Let me quickly tell you what happened.
We have had two M6s in our clinic for some time and we do respiratory therapy with them. It is a practice that focuses on the respiratory muscles that need to be treated so that the patient can walk, move and feel less pain.
At this point, we actually realized that we were doing things wrong, given that in a post-COVID patient the primary need is to eliminate the inflammation from the lung tissue.
It was then that we started looking for other equipment or other types of therapies, in addition to drugs such as steroids, capable of reducing or eliminating inflammation of the lung tissue without putting our patient at risk: basically, we were looking for something really effective. Thanks to some of our colleagues from Boston and other European countries who started using laser therapy, in this case ASA’s M6, the first positive results began to show. A decidedly safe therapy, that did not endanger the patient. It was then that we began to use it on our post-COVID patients too, patients that were obviously no longer able to transmit the virus, but that had great respiratory limitations, disorders of various kinds caused by the virus itself, i.e. with atypical pneumonia. Although they no longer tested positive for the atypical pneumonia virus, it was still an ongoing process and we suspected it was a pulmonary fibrosis process.
At this point, we started using it with the aim of eliminating the inflammation of the lungs, therefore, no longer as a respiratory therapy but as a lung therapy. And it is a device that began to give us very positive results from the very first sessions.
The patient began to absorb more oxygen, improving their saturation and decreasing the supplemental oxygen day after day, as well as their heart rate. Between the second and the third session we obtained the first incredible results, because up to that point we did not have them, we were not able to achieve them.
We have patients who had 3-4 months of respiratory therapy performed thanks to the use of drugs, negative for 3-4 months or with a transmissible COVID infection, or struggling with the consequences of an atypical pneumonia in progress and, in these cases, the laser therapy was truly impressive, seriously, amazing: how is it possible that a machine can lead to a reduction of lung inflammation, cause a cytokine storm, and bring all the benefits we are talking about?
So, for many it was astonishing and it was absolutely necessary to quickly share all this with other doctors. Other colleagues who may want the same equipment to offer these same results to their patients.
Given that EsportMedicine has robotic MLS® Laser Therapy, you just told us that you relied heavily on the scientific experience of ASA and other various colleagues, both from the United States and the Czech Republic, where they started to treat COVID patients and everything that has since become post-COVID. In light of this premise the question is: What encouraged you to start with treatments on patients of this type, given that not everyone decides to treat them, and to give them a chance? What would you recommend to future therapists, since this is a growing problem, as it can already be seen in this period, and will be even more so in the long run? I would like to share your experiences or some of your thoughts with the aim of encouraging other colleagues in starting the rehabilitation of patients of this type. What would you recommend to them?
Actually, the answer is very simple. The market offers many solutions in the field of rehabilitation and there are various types of rehabilitation. Unfortunately, however, almost nothing is working. I say this because I see patients with pulmonary fibrosis and patients who continue to have ongoing atypical pneumonia. It must be said that we do not know why, since it is an emerging disease; we do not know what to expect.
However, it is incredible to see how a therapy of this type, a laser therapy, a high-power phototherapy can bring these advantages. There is no need to convince anyone; there is no need to present 200 cases.
In other words, when we tested the effect on the market, the results of the treatment were incredible, and it is not just us saying it, it is the United States, Europe, and the publications.
But we did not reinvent the wheel: we are well aware that high-power therapy, especially that implemented with our M6 laser, hits the inflammatory storm of our patients. All we had to do was move from a knee to the lung tissue, adjust the parameters, and see what the benefits were for the patients.
